Physicochemical trends of compound efflux in gram-negative bacteria and characterization of novel antibacterials

Ulrich, Rebecca Joy

Permalink

https://hdl.handle.net/2142/125786 Copy

Description

Title

Physicochemical trends of compound efflux in gram-negative bacteria and characterization of novel antibacterials

Author(s)

Ulrich, Rebecca Joy

Issue Date

2024-07-09

Director of Research (if dissertation) or Advisor (if thesis)

Hergenrother, Paul J

Doctoral Committee Chair(s)

Hergenrother, Paul J

Committee Member(s)

• Burke, Martin D
• Metcalf, William W
• Manesis, Anastasia C

Department of Study

Chemistry

Discipline

Chemistry

Degree Granting Institution

University of Illinois at Urbana-Champaign

Degree Name

Ph.D.

Degree Level

Dissertation

Keyword(s)

• Gram negative bacteria
• compound efflux
• accumulation
• LolCDE
• FabI

Abstract

Multi-drug resistant bacterial infections are a rising threat to human health and account for 1.3 million deaths annually, and 70% of these deaths are due to gram negative pathogens. No new FDA-approved classes of gram-negative active antibiotics have entered the clinic in the past 55 years, due to challenges with converting in vitro biochemical activity to whole cell gram negative activity. Gram negative drug discovery is hindered by both an impermeable outer membrane, which limits compound uptake, and promiscuous efflux pumps, which rapidly expel antibiotics. While previous work in the Hergenrother lab has developed actionable guidelines for imbuing gram negative activity into antibacterials, compound efflux remains a significant issue limiting efficacy of small molecules. Herein, we report the development and validation of an LC-MS/MS assay to quantify efflux liabilities (EffluX Propensity EvaLuation, EXPEL) and application of the EXPEL assay to a complex and diverse collection of compounds to identify physicochemical properties that correlate with efflux. Through chemoinformatic data analysis, actionable guidelines for engineering efflux liabilities out of small molecules were identified. Using these guidelines, we are strategically modifying gram-negative active and microbiome sparing LolCDE and FabI inhibitors, both which have excellent preclinical properties, to evade efflux. Additionally, we present other candidate compounds for applying the EXPEL rules and provide a blueprint for optimizing compound uptake and efflux evasion in antibacterial candidates. Additionally, ongoing work in the Hergenrother lab focuses on the development of gram negative active antibacterials and continued expansion of our understanding of porin-mediated uptake in E. coli. Work towards the development of 3 antibacterials as gram negative antibiotics—lolamicin, fabimycin, and Ribocil-PA—is presented herein, as well as work towards understanding mechanisms of porin-mediated uptake and the role of stereochemistry on uptake and efflux in E. coli.

Graduation Semester

2024-08

Type of Resource

Thesis

Handle URL

https://hdl.handle.net/2142/125786

Copyright and License Information

Copyright Rebecca J. Ulrich 2024

Owning Collections